Answers from the Lab

By Mayo Clinic LaboratoriesScience Medicine Health & Fitness

Answers from the Lab episodes

October 25, 2022 Focused lung panel informs the use of targeted cancer therapies: Ying-Chun Lo, M.D., Ph.D.
(00:32)
Could you provide us some background about yourself?
(01:34)
Could you give us a brief overview of the new Mayo complete lung cancer assay?
(03:31)
Can you talk a little bit more about the specific genes and why they're important for patient care?
(04:53)
When would a clinician pathologist order a focused NGS panel, such as this new Mayo complete lung cancer panel, over a larger cancer panel?
(07:27)
What specimens are accepted for the Mayo complete lung cancer panel?
(08:50)
How are these molecular results used in patient care?
12 min
October 18, 2022 Unique pediatric evaluation targets relevant autoimmune/CNS antibodies: Andrew McKeon, M.B., B.Ch., M.D.
(00:31)
Could you tell us a little bit about yourself and your background?
(01:15)
Can you give us a little understanding of this disease state and why a tailored evaluation for pediatric patients is important?
(02:47)
What makes it more challenging to diagnose a pediatric autoimmune neurological disorder?
(03:32)
Is the tailored evaluation necessary because different antibodies are evaluated?
(04:08)
How common are these disorders in pediatric patients?
(04:40)
How does our assay for adults differ from the pediatric assay?
(05:17)
Do we evaluate for the ANNA-1 paraneoplastic antibody in both children and adults?
(05:59)
Are our decisions on which antibodies to include based on our clinical experience?

(06:46)
Which patients would this kind of testing be appropriate for?
(07:29)
Should antibody testing be ordered early in the process of differential diagnosis?
(08:29)
Do other disorders mimic these autoimmune disorders?
(09:00)
What do test results mean in terms of next steps for physicians and patients?
(09:55)
What are the most critical antibodies to test for in this pediatric population?
(10:30)
Is it important for physicians to send both serum and CSF samples?
(10:48)
In what specimen type is MOG most readily detected?
(11:18)
What are the repercussions of not using a tailored evaluation?
(13:04)
Do we use any patterns we see in test results to build future evaluations?
(14:15)
Does a tailored evaluation mean faster test results?
(15:21)
Are there any other key takeaways that you want to share with physicians to help them understand the importance of this evaluation and how it can be used in their clinical practices?
17 min
October 13, 2022 Preparing for respiratory infection season: Dr. Matthew Binnicker
On this week’s episode of the "Answers From the Lab" podcast, Bobbi Pritt, M.D., is joined by Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory at Mayo Clinic. Dr. Pritt and Dr. Binnicker discuss why it could be a rough influenza season, testing options for patients with respiratory infections, and how to protect yourself from illness.
9 min
October 11, 2022 Chain of Custody Testing: Loralie Langman, Ph.D.
(0:32)
Will you tell us a bit about yourself and your background?

(01:35)
Can you help us understand what type of tests you perform in your laboratory and how the results can be used to support patient care?

(02:18)
When is it important to consider urine drug testing, and what is our recommended approach?

(03:59)
Could you help us understand more about forensic toxicology and when to consider testing?

(04:46)
Is chain of custody testing recommended for only a small number of patients?

(04:58)
What other tests are available, and where can people learn which testing to order?
7 min
October 06, 2022 Shifting from pandemic to endemic: Dr. Bill Morice
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss the stabilization of monkeypox and COVID-19, the shift from pandemic to endemic status, the increase in global virus outbreaks, and the role that laboratory medicine plays in this changing health environment.
12 min
September 29, 2022 Virus outlook heading into fall: Dr. Bill Morice
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice cover current trends for monkeypox and COVID-19, their thoughts as autumn begins, getting back to infection prevention basics, and a quick legislation update.
12 min
September 22, 2022 Advocating for lab legislation: Dr. Bill Morice
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss the Saving Access to Laboratory Services Act (SALSA), how it is designed to mitigate harmful effects of the Protecting Access to Medicare Act (PAMA), where the legislation stands today, and how to get involved in advocacy.
11 min
September 20, 2022 PIK3CA assay guides treatment of progressing breast cancer: Katherine Geiersbach, M.D.
(00:32)
Could you provide a little bit of background about yourself, please?
(01:01)
Please give us a brief overview of the new PIK3CA assay.

(02:09)
Why do we offer two different tests, and when should each be ordered?
(03:58)
Which patients should have this testing?
(04:39)
Is this testing used for patients being considered for second-line treatment after first-line hormone receptor treatment?
(05:20)
Is there anything else you would like to add about the PIK3CA testing?
(06:23)
Why is it important to know the molecular signature of these tumors?
9 min
September 19, 2022 Leading diagnostics into the future: Dr. Bill Morice
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, they discuss Dr. Morice’s new role as CEO and president of Mayo Clinic Laboratories (MCL), his patient-centered vision for the future, and how MCL is leading positive changes in the diagnostics industry.
14 min
September 15, 2022 PCD test provides definitive diagnosis of a rare disease: Joseph Maleszewski, M.D., and Marie-Christine Aubry, M.D.
(00:31)
Could each of you please provide a little bit of background about yourself?
(01:18)
Let's start with a general definition of primary ciliary dyskinesia (PCD) for our audience.
(02:21)
PCD is rare. Dr. Maleszewski, can you talk about the implications of that?
(02:39)
What is the current state of PCD diagnosis in the U.S. and globally, and what are the implications for patient care?
(03:37)
Can you say a bit more about Mayo Clinic's diagnostic approach to PCD?
(05:16)
Mayo Clinic is the first and only diagnostic center of excellence accredited by the primary PCD foundation. What is the significance of that?
(07:01)
Can you expand upon future plans for PCD diagnosis at Mayo Clinic?
9 min

About Answers from the Lab

From the publisher's feed

A Mayo Clinic curated podcast sharing Mayo Clinic knowledge and advancements on the state of testing, science, and people who are making it happen behind the scenes.